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Abstract
Background: Bone marrow (BM) niches are often inaccessible for controlled experimentation due to their difficult
accessibility, biological complexity, and three-dimensional (3D) geometry.
Methods: Here, we report the development and characterization of a BM model comprising of cellular and
structural components with increased potential for hematopoietic recapitulation at ectopic transplantation sites.
Cellular components included mesenchymal stromal cells (MSCs) and hematopoietic stem and progenitor cells
(HSPCs). Structural components included 3D β-tricalcium phosphate (β-TCP) scaffolds complemented with Matrigel
or collagen I/III gels for the recreation of the osteogenic/extracellular character of native BM.
Results: In vitro, β-TCP/Matrigel combinations robustly maintained proliferation, osteogenic differentiation, and matrix
remodeling capacities of MSCs and maintenance of HSPCs function over time. In vivo, scaffolds promoted strong and
robust recruitment of hematopoietic cells to sites of ectopic transplantation, vascularization, and soft tissue formation.
Conclusions: Our tissue-engineered BM system is a powerful tool to explore the regulatory mechanisms of
hematopoietic stem and progenitor cells for a better understanding of hematopoiesis in health and disease.
Background
The different components of the bone marrow (BM)
microenvironment—consisting of (a) hematopoietic cells,
(b) stromal cells and vasculature, (c) extracellular matrix,
and (d) bone—are critical to explore for a better under-
standing of hematopoiesis during health and disease.
These components are often inaccessible for controlled
and rapid experimentation, thus limiting studies to the
evaluation of conventional cell culture and transgenic ani-
mal models. The rationale to develop ectopic transplant-
able BM niches arises from the need to dissect regulatory
mechanisms in the BM and the hematopoietic-stroma
interaction. So far, no gold standard exists to specifically
analyze the role of the BM stroma in vivo or to genetically
modify stroma in its natural environment as stroma is not
sufficiently transplantable in contrast to hematopoietic
cells [1, 2].
Few approaches including in vivo imaging [3, 4], the de-
sign of three-dimensional (3D) environments using bio-
materials [5–10], and BM-on-a-chip [11] for the study of
hematopoiesis have been introduced to date, but these
system lack full BM recreation, as hematopoietic stem and
progenitor cell (HSPC) interaction with the endosteal
niche or with the supporting stroma is compromised or
simply the geometry beneficial for a controlled manipula-
tion is still missing.
Bioceramics such as β-tricalcium phosphate (β-TCP)
are particularly interesting for bone tissue engineering as
they provide characteristics for cellular interactions
while ensuring superior biomechanical properties [12].
Matrigel is a basement membrane protein mixture typic-
ally used in vivo to stimulate tissue formation. [8]. Here,
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we combined 3D β-TCP scaffolds with defined and con-
trolled geometry (bone component) with an extracellular
matrix component composed of either collagen I/III or
Matrigel (matrix component) to establish co-cultures of
HSPCs and mesenchymal stromal cells (MSCs) (cellular
component). The ultimate goal of the current study is to
create artificial, transplantable BM niches that support
hematopoiesis while allowing for the genetic modifica-




β-TCP scaffolds were fabricated using slip casting into
3D-printed wax molds. First, two virtual models were
constructed using computer-aided design (3-matic, Ma-
terialise, Leuven, Belgium). The models had a cylindrical
shape with an inner diameter of 9.6 mm and a height of
4.9 mm. A rectangular lattice with 500-μm struts was in-
corporated into one of the models. The struts had a spa-
cing of 2 mm and were connected to the cylinder. Into
the second virtual model, a lattice with 800-μm struts
(spacing 2.5 mm) was incorporated in the same way. Fi-
nally, a sprue with a diameter of 9.6 mm and a height of
2.1 mm was added on one side of the cylinders. Both
models were printed using a 3D wax printer (T76®PLUS,
Solidscape, Idar-Oberstein, Germany) to generate the
wax molds for the slip casting process. A suspension
consisting of 68.7 wt% β-TCP, 29.3 wt% distilled water,
and 2 wt% organic additives (0.2 wt% Contraspun,
1.4 wt% Optapix, 0.4 wt% Dolapix, Zschimmer und
Schwarz, Lahnstein, Germany) was synthesized. The sus-
pension was homogenized for 30 s using a SpeedMix-
erTM, (DAC 150.1 FVZ, Hauschild, Hamm, Germany) at
a mixing rate of 3000 rpm. Afterwards, the suspension
was filled with a pipette into the wax molds. The filled
molds were devolatilized in a desiccator, and the suspen-
sion within was dried for 24 h at room temperature. The
sprue was cut off with a scalpel until the ends of the ver-
tical wax struts were exposed. The samples were heat
treated for 30 min at 105 °C to melt out the wax (heat-
ing rate 2.5 K/min) and subsequently sintered for 3 h at
1200 °C (heating rate 3 K/min). The generated β-TCP
scaffolds were cleaned in an ultrasound bath to remove
particulate matter and dried at 80 °C for 24 h. Finally,
the scaffolds were sterilized by autoclaving and dried at
80 °C for 24 h before they were used for cell culture.
Collagen I/III gels and Matrigel®
Collagen I/III were produced as previously described
[13–16], and human mesenchymal stromal cells (hMSCs)
or murine BM-derived mesenchymal stem cells (mBMSCs)
were seeded at a density of 1 × 106 cells/mL. Matrigel®
basement membrane matrix complex (BD Biosciences,
354234) was handled according to the manufacturer’s in-
structions, and mBMSCs were seeded at a density of 1 ×
106 cells/mL. Two hundred microliters of either collagen I/
III gel or Matrigel® was combined with each one β-TCP
scaffold. Gel polymerization was achieved by 1-h incuba-
tion at 37 °C in a 20 %-O2/5 %-CO2-humidified
atmosphere.
Isolation and culture of hMSCs
MSCs from human femoral head spongiosa were col-
lected after hip replacement surgeries and followed ap-
proved guidelines of the Ethics Committee of RWTH
Aachen University. Cell isolation was performed accord-
ing to previously described protocols [13–16]. For all ex-
periments, hMSCs were passaged between 2–4 times
before use. hMSCs were seeded on the β-TCP scaffolds
at a density of ca. 1.5 × 105 cells/scaffold. Osteogenic dif-
ferentiation was performed according to published pro-
tocols [8, 14].
Isolation and culture of human CD34+ progenitors
CD34+ progenitors were obtained by immunomagnetic
bead selection (Miltenyi Biotec, Bergisch-Gladbach,
Germany) from human umbilical cord blood units col-
lected according to the guidelines of the Ethics Committee
of RWTH Aachen University (EK187/08). CD34+ progeni-
tors were cultured in StemSpan serum-free medium in the
presence of SCF (50 ng), TPO (20 ng), Flt3-L (50 ng), and
IL-6 (10 ng, all Peprotech, London, UK) as before [7, 8].
Isolation and culture of mBMSCs
mBMSCs were isolated from BM aspirates of 6–8-week-
old C57BL/6 mice by mechanical crushing and collagenase
treatment to liberate the stromal cells from the endosteal
bone as described before [17]. Cells from six pooled mice
were used for each experiment. mBMSCs were expanded
in DMEM/F-12 with Glutamax™ (Life Technologies) sup-
plemented with 1 nM dexamethasone (Sigma, Steinheim,
Germany), 1 ng/mL fibroblast growth factor-2 (Peprotech,
London, UK), 5 ng/mL epidermal growth factor (Pepro-
tech), 2 % fetal calf serum (PAN Biotech), and 2 % penicil-
lin/streptomycin (Life Technologies). mBMSCs were used
between passages 2–4 for seeding.
Isolation and culture of murine c-kit+ cells
The hematopoietic cell fraction was collected by mechan-
ical crushing/flushing of long bones and the pelvis, and c-
kit+ cells were isolated by immunomagnetic bead selection
using mouse CD117 (c-kit) microbeads (Miltenyi Biotec,
Bergisch-Gladbach, Germany). Purity was confirmed by
flow cytometry. Freshly isolated c-kit+ cells were used for
co-cultures at ca. 1.5 × 105 cells/well and maintained in
StemSpan serum-free expansion medium (SFEM) (Stem
Cell Technologies Inc., Vancouver, Canada) containing
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50 ng/mL stem cell factor (Peprotech), 50 ng/mL thrombo-
poietin (Peprotech), and 1 % penicillin/streptomycin (Life
Technologies).
Culture conditions in β-TCP scaffolds
β-TCP scaffolds were transferred to 48-well tissue cul-
ture plates (Corning, Wiesbaden, Germany), and hMSCs
embedded in the collagen I/III gels or directly seeded on
the β-TCP scaffolds were kept in culture for 8 weeks.
mBMSCs embedded in gels were pre-expanded for
1 week, and c-kit+ cells were seeded and co-cultures
kept at 37 °C in a 20 %-O2/5 %-CO2-humidified atmos-
phere. Cells were recovered by vigorous pipetting and
subsequent gel digestion using collagenase II (Life Tech-
nologies) for collagen I/III gels and dispase II (Life Tech-
nologies) for Matrigel® gels.
Flow cytometry
For analysis of maintenance of primitive phenotype in
the human setting, 5-day cultured CD34+-isolated cells
co-cultured with hMSCs for 5 days in β-TCP scaffolds
with or without matrix component were assessed for the
combined expression of CD34-FITC and CD38-PE (Milte-
nyi Biotec). For analysis of primitive phenotype and differ-
entiation ability in the murine setting, c-kit+ cells from in
vitro co-cultures were recovered at days 4, 7, 10, 14, and
18. In the in vivo setup, cells were recovered from
explanted scaffolds 4 and 8 weeks after transplantation.
Antibodies CD117-allophycocyanin, Sca1-phycoerythrin,
lineages (CD3, CD5, B220, G1, CD11b, Ter119)-eFluor®450,
Gr-1-allophycocyanin-cyanine7, CD11b-allophycocyanin,
CD19-phycoerythrin-cyanine7, CD3-phycoerythrin, and
Ter119-peridinin chlorophyll-cyanine5.5 (all eBiosciences,
Frankfurt, Germany) were used at 1:100, except for lineage
antibodies used at 1:200 as recommended, in PBS/1 %-FCS
for 30 min at 4 °C. A minimum of 100,000 events were
acquired on a FACSCantoII flow cytometer (Becton
Dickinson). Data were further analyzed using FlowJo
(Tree Star Inc., Ashland, USA).
Methylcellulose colony assays
C-kit+ cells derived from 4-day or 14-day cultures were
plated at 1 × 105 cells per 35-mm petri dish in duplicates
of serum-free methylcellulose medium (MethoCult GF
M3434, Stem Cell Technologies Inc., Vancouver, Canada).
After 12 days of incubation at 37 °C and 5 % CO2 in a hu-
midified atmosphere, colonies were scored using an
inverted light microscope (Leica, Wetzlar, Germany).
Colony-forming unit granulocyte-macrophages (CFU-
GM) and colony-forming unit granulocyte-erythrocyte-
macrophage-megakaryocyte (CFU-GEMM) were assayed
according to morphological criteria.
SEM and FESEM in cryo-mode
β-TCP scaffolds from in vitro cultures and in vivo explan-
tations were prepared for scanning electron microscopy
(SEM) by fixation in 3 % glutaraldehyde for at least 24 h
at 4 °C. A graded ethanol series of 30, 50, 70, 90, and
100 % followed for sample dehydration. Sample preserva-
tion was achieved by hexamethyldisilizane (HMDS) dry-
ing. Before gold sputtering and fixation on SEM stubs,
scaffolds were sectioned one time longitudinal and orien-
tated in the cross-sectional area for visualization. A field
emission SEM microscope (ESEM XL 30 FEG, FEI, Phi-
lips, Eindhoven, The Netherlands) with a high-vacuum en-
vironment was used.
For a more detailed analysis of gel structure, field
emission scanning electron microscopy (FESEM) in
cryo-mode was performed for collagen I/III and Matri-
gel®. Gels were rapidly frozen in liquid nitrogen and
transferred to the high-vacuum Balzers BF freeze-
etching chamber of a FESEM instrument in cryo-mode
(HITACHI S-4800, Hitachi, Tokyo, Japan) with second-
ary electron image resolution of 1.0–1.4 nm at voltages
of 1–15 kV. Gels were sublimated for 1 h at 80 °C before
image acquisition.
TEM
Freshly isolated, 4- and 14-day cultured c-kit+ cells were
recovered from the scaffolds as already described, pel-
leted and fixed in 3 % glutaraldehyde, and processed for
transmission electron microscopy (TEM) as described
previously [13]. Cells were visualized using a transmis-
sion electron microscope at 60 kV (EM 400 T, Philips,
Eindhoven, The Netherlands).
IHC
At the indicated time points, culture medium was re-
moved and samples fixed in 10 % formalin for at least
24 h at 4 °C. Scaffolds were decalcified using EDTA for
48 h, sectioned, ethanol fixed and embedded in paraffin
according to the standard protocols of the Institute of
Pathology, University Hospital Aachen. Paraffin sections
of 3 μm were deparaffinized, hydrated using decreasing
ethanol series and subject to heat-induced antigen re-
trieval using citrate buffer pH = 6.0. Immunohistochem-
istry stainings were performed using an Autostainer
platform for immunohistochemistry (IHC) (Dako Cyto-
mation). Primary antibodies used were specific for CD31
(1:100, rabbit polyclonal, Abcam), CD45(1:100, rabbit
polyclonal, Abcam). Primary antibodies were diluted in
Dako antibody diluent and incubated for 1 hour at room
temperature. StreptABC complex/HRP followed by DAB
for color development was used according to the Dako
real detection system instructions (Dako Cytomation,
K5001). Reticulin stain and hematoxilin-eosin stains
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were additionally performed according to routine hist-
ology protocols.
RT-qPCR
Isolation of total RNA from cultures was done with Tri-
pure Isolation Reagent (Roche, Mannheim, Germany)
[13, 14]. In brief, a high-capacity cDNA Reverse Tran-
scriptase Kit (Applied Biosystems, Darmstadt, Germany)
was used for RNA reverse transcription product amplifi-
cation that was done using a 7300 Real-Time PCR Sys-
tem and SYBR green (Applied Biosystems, Darmstadt,
Germany) running an amplification cycle consisting of
10-min denaturation at 95 °C, additional 40 cycles of de-
naturation at 95 °C for 15 s, and final extension of 1 min
at 60 °C. The housekeeping gene GAPDH was used for
normalization of data. Gene expression on collagen I/III
gel controls was set to one using the 2−ΔΔct method [8].
Primers used (Eurofins MWG Operon, Ebersberg,
Germany) are listed in Additional file 1: Table S1.
Calcium and phosphate assays
Calcium and phosphate content of culture supernatants
was measured at weeks 1, 2, and 3 after cell seeding
using a standard autoanalyzer. Alternatively, a commer-
cially available colorimetric-based calcium assay kit
(RANDOX, Crumlin, UK) was used to determine the
amount of calcium released from the β-TCP scaffolds.
The assay was carried out according to the manufacturer’s
instructions and absorbance measured at 578 nm using an
Infinite® M200 microplate reader (Tecan, Männedorf,
Switzerland).
Mouse transplantations
Six- to eight-week-old C57BL/6 mice were obtained from
Jackson Laboratories (Maine, USA). Animals were kept at
the Animal Research Facility Children’s Hospital, Harvard
Medical School, Boston, USA. Animals were handled ac-
cording to institutional regulations and transplantations
done according to standard protocols (mouse protocol
number 13-04-2393R). mBMSCs were expanded in vitro
for 1 week and then seeded on 500- and 800-μm β-TCP
scaffolds in combination with collagen I/III or Matrigel®.
Cell/matrix/scaffold hybrids were transplanted subcutane-
ously into the C57BL/6 mice.
Statistical analysis
Data presented was obtained from at least three inde-
pendent donors. Results express mean ± SD, unless
stated otherwise. Statistics as well as graphical represen-
tations were performed using GraphPad PrismTM 5.0
(GraphPad Software Inc., San Diego, USA). Statistical
significance of data results from one-way ANOVA
followed by Tukey’s post hoc test (analysis of three or
more groups). Significant differences were considered
when p < 0.05.
Results
β-TCP scaffold characterization
We first characterized the 3D porous β-TCP scaffolds,
which were designed to mimic the spongious, structural
part of the bone in terms of (i) osteoconductivity (porosity
allowing for cell penetration and/or attachment and
growth), (ii) osteogenicity (local osteoblastic mineral forma-
tion allowing for matrix calcification) [18], (iii) transplant-
ability, (iv) inertness, and (v) hematopoiesis-supporting
capacities. As pore size is known to affect cell attachment,
proliferation, and migration [19], we tested the biological
performance of β-TCP scaffolds with two different pore
sizes—500 and 800 μm in diameter—similar to the geom-
etry of the human bone and as used for replacement strat-
egies [20, 21]. We applied scaffolds with 500- and 800-μm
pore sizes in order to (a) simulate human bone properties,
(b) maximize the surface area and volume available for
stromal cell expansion, and (c) support bone ingrowth. As
the literature reports strongly variable pore sizes ranging
from 300 to 900 μm to be optimal, we analyzed if pore size
matters for the recapitulation of extramedullary niches
containing two cell types—adhering stromal cells and
hematopoietic stem and progenitor cells [22].
β-TCP scaffolds were generated with interconnected
macropore geometries for better cell growth, migration,
and nutrient flow (Fig. 1a–g). The porosity of 500- and
800-μm scaffold was 14 and 17 vol.-%, respectively (Fig. 1e),
comparable to the porosity of human cortical bone that is
known to go from up to 8 % in young individuals to 24–
28 % in elderly individuals [23, 24]. Maximized 500/800-μm
scaffold magnitudes were provided for 3D culture including
a surface area of 648/584 mm2 for stromal cell expansion
and a volume of 51/60 mm3 for HSPC expansion.
For scaffold characterization experiments, we seeded
hMSCs onto 500- and 800-μm β-TCP in the presence or
absence of collagen I/III (Fig. 1c, d, f ). We first assessed
the inertness of β-TCP scaffolds indicated by release of
Ca2+ and PO4
3− in culture supernatants after 3, 11, and
21 days of culture (Fig. 1g). Analysis confirmed a minor
increase in Ca2+ concentration in the culture medium of
β-TCP-containing scaffolds, ca. 0.1 mmol/L for 500- or
800-μm β-TCP scaffolds. The PO4
3− concentration
(Fig. 1g) increased over time in all β-TCP-containing su-
pernatants (increase of 0.2–0.4 mmol/L) within ranges
that are negligible and cannot be considered as indica-
tors of spontaneous osteogenesis.
Assessment of the β-TCP scaffold potential for osteogenic
differentiation
To determine if β-TCP induces a spontaneous osteo-
genic differentiation, we next analyzed the effect of β-
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TCP and collagen I/III on hMSC growth, osteogenic dif-
ferentiation, and matrix production assessed by gene ex-
pression (Fig. 2). β-TCP scaffolds had good
osteoconductivity as indicated by hMSC attachment, mi-
gration, and survival in the interconnected macropores
of β-TCP scaffolds (Fig. 1f; Additional file 2: Figure S1).
Fig. 1 Characterization of β-TCP scaffolds. a Negative mold used for wax casting during production of the different β-TCP scaffold geometries.
b Macroscopic view of the β-TCP scaffolds. c SEM view of the β-TCP scaffolds. d Schematic illustration of the long-term cultures consisting of
three main components: mesenchymal stromal cells (MSCs; pink), β-TCP (blue), and collagen I/III (green). e Table of porosites. f Cell morphology
and cell spreading on scaffolds analyzed by SEM. g Release of calcium (Ca2+) and phosphate (PO4
3−) to the culture supernatant. Concentrations
were measured in the supernatants of β-TCP cultures at days 3, 11, and 21 after the beginning of the culture. Concentrations were normalized to
1 at day 3 and are presented in mmol/L. Results depict mean ± SD of three independent experiments
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To analyze if the scaffold induced a spontaneous
osteogenic differentiation of hMSCs, we seeded hMSCs
in direct contact to 500/800-μm β-TCP scaffolds (Fig. 2).
To dissect the additional effect of an extracellular
matrix, we compared the spontaneous differentiation po-
tential side-by-side to β-TCP/collagen I/III scaffolds and
looked at hMSCs subjected to standard osteogenic dif-
ferentiation protocols as a positive control (Fig. 2).
BMP-2 and RUNX2 as early markers of osteogenic dif-
ferentiation as well as the late marker osteopontin were
not significantly up-regulated after 3 weeks of culture
under nearly all β-TCP conditions, independent of the
presence of collagen I/III gels (not shown). After 8 weeks
of culture, the induction of early and late markers was
maintained for cells cultured in β-TCP scaffolds in the
absence of collagen I/III gels and decreased in the pres-
ence of collagen I/III gels (Fig. 2). This effect might be
due to significant matrix remodeling that occurs in the
presence of collagen I/III-containing scaffolds as indi-
cated by the up-regulation of collagen I, fibronectin,
laminin, and collagen IV in 8-week cultures (Fig. 2).
Taken together, gene expression analysis provides no evi-
dence for spontaneous osteogenesis upon in vitro cul-
ture or co-culture of hMSCs.
Characterization of the β-TCP/matrix hybrids as extrame-
dullary hematopoietic niches in vitro
We aimed to generate transplantable extramedullary
hematopoietic niches and next analyzed the effect of β-
TCP constructs on murine hematopoiesis in vitro. We
combined 500- and 800-μm β-TCP scaffolds with either
collagen I/III [8] or Matrigel® to improve cell engraft-
ment and proliferation [25]. mBMSCs were cultured for
1 week on β-TCP scaffolds (with and without collagen I/
III) before freshly isolated c-kit+ HSPCs from murine
BM were added. In order to decide on the optimal
Fig. 2 Osteogenic marker and extracellular matrix expression analysis of long-term MSC cultures on β-TCP scaffolds. The osteogenic markers
BMP-2, RUNX2, and OPN as well as the extracellular matrix proteins collagen I, fibronectin, collagen IV, and laminin were analyzed after 8 weeks
in culture. Data were calibrated relative to MSCs growing in collagen I/III gels, where gene expression was set to 1 for all genes. GAPDH was
used as a housekeeping gene for normalization. Gene expression is presented as mean ± SD of three independent experiments and depicted
on a logarithmic scale
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combination of extracellular matrix and β-TCP pore size
for future transplantation experiments, we assessed (i)
viability, (ii) maintenance of a primitive HSPC pheno-
type and lineage differentiation, (iii) proliferation, and
(iv) extracellular matrix remodeling.
Maintenance of the primitive hematopoietic stem and
progenitor cell phenotype was monitored after 5 and
12 days for the human setting (Additional file 3: Figure
S2A) and 4, 7, and 14 days for the murine setting (Fig. 3a–
c; Additional files 4 and 5: Figures S3–S4). Murine
hematopoietic stem cells can be characterized in the bone
marrow by being lineage-marker negative, c-kit+ and Sca1
+ (LSK population; lin−Sca1+c-kit+), while hematopoietic
progenitor cells are lineage-marker negative, Sca1− and c-
kit+ (LK population; lin−Sca1−c-kit+). After 14 days, the
viability in the β-TCP scaffolds alone or in combination
with Matrigel® was independent of the pore size (Fig. 3a).
The presence of a collagen matrix reduced the cell viabil-
ity, probably due to significant matrix remodeling, as dis-
cussed before. The stromal cells in the collagen scaffolds
can be characterized as lin−Sca1+c-kit−. We quantified the
percentage of lin−Sca1+c-kit− stromal cells at day 4 and
monitored their increase/decrease over time (Fig. 3b, c).
In particular, 500-μm scaffolds had a positive effect on
stromal cell expansion. We next assessed the maintenance
of the LSK and LK phenotypes in vitro. Our results
showed that β-TCP/extracellular matrix hybrids more ro-
bustly maintained a phenotypical LSK fraction over time
compared to β-TCP alone (Additional file 4: Figure S3).
C-kit+ expression was shown to decrease over time in
Fig. 3 Hematopoietic stem cell characterization in β-TCP scaffolds in vitro. C-kit+ cells were subjected to the different β-TCP/matrix hybrids over 14 days
in vitro. a Percentage of DAPI−-viable cells after 14 days of c-kit+ cell culture with and without collagen I/III/Matrigel® on β-TCP scaffolds in the presence
of MSC support. b Expansion/decrease of lin−Sca1+c-kit− stromal cells normalized to day 4 of the culture. c Expansion/decrease of lin− normalized to
day 4 of the culture. Mean ± SD of three independent experiments. d Colony-forming potential of cells isolated from 500- and 800-μm β-TCP scaffolds
with and without collagen I/III/Matrigel® in the presence of MSC support at day 4 and day 14. Results are mean ± SD of three independent experiments.
CFU colony-forming unit, GEMM granulocyte-erythrocyte-macrophage-megakaryocyte, GM granulocyte-monocyte. without
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vitro independent of the hematopoietic stem and progeni-
tor phenotype [26]. We thus quantified lineage-negative
cells in the scaffolds over time as this population is
enriched in hematopoietic stem and progenitor cells. The
presence of 500-μm scaffolds showed a relative expansion
of lineage-negative cells while this population maintained
stable in the other conditions. We confirmed these results
by using human HSPCs. In humans, the subset of CD34
+CD38− HSPCs corresponds to a more primitive pheno-
type. Our data in short-term co-cultures showed that
CD34+CD38− HSPCs were maintained most sufficiently in
β-TCP scaffold containing collagen I/III (Additional file 3:
Figure S2A), comparable to our results in the murine
system.
In order to evaluate not only the HSPC phenotype but
also their function among the different scaffold combi-
nations as the ultimate readout for the maintenance of
hematopoietic stem cell capacities, we performed
colony-forming assays at day 4 and day 14 (Fig. 3d). Our
data showed that murine cells cultured on β-TCP scaf-
folds alone for 4 days had significantly impaired CFU
potential and HSPC function compared to all the other
conditions. The presence of Matrigel® alone resulted in
the significantly highest total number of colonies, and the
combination of β-TCP/Matrigel® led to the highest num-
ber of CFU-GEMM colonies, representing multipotent
myeloid progenitor cells. As expected, the CFU potential
globally decreased after 14 days, but HSPCs cultured in
the combination of β-TCP/Matrigel® scaffolds (p < 0.001
compared to 500-μm β-TCP and p < 0.002 compared to
800-μm β-TCP) gave rise to the significantly highest num-
ber of colonies, in particular to primitive CFU-GEMM
colonies, indicating that the function of HSPCs was main-
tained under these conditions.
We next analyzed the lineage differentiation potential and
asked whether or not scaffold combinations induce a lineage
bias (Fig. 4a; Additional file 5: Figure S4). We analyzed gran-
ulocytes (Gr1+CD11b+), monocytes (Gr1−CD11b+), B-cells
(Gr1−CD11b−CD19+), T cells (Gr1−CD11b−CD3+), and
erythroid cells (Gr1−CD11b−CD3−CD19−) in the murine in
vitro culture system at day 4 and day 14. All culture condi-
tions induced myeloid differentiation into granulocytes and
monocytes. The frequency of granulocytes decreased in ten-
dency over the culture of 14 days, while the frequency of
monocytes increased. After 14 days, the presence of Matri-
gel® in 500 and 800 μm significantly stimulated monocyte
differentiation as compared to β-TCP scaffolds alone. We
also detected both lymphoid (mainly T cells) and erythroid
differentiation in all culture conditions, indicating that the
scaffold-matrix hybrids support both trilineage differenti-
ation as well as maintenance of primitive, functional HSPCs.
Next, we dissected the spatial distribution of human
CD34+ HSPCs and murine c-kit+ cells in β-TCP/matrix hy-
brids combinations (Fig. 4b; Additional file 3: Figure S2B;
Additional files 6, 7, and 8: Figures S5–S7). HSPCs growing
on β-TCP/Matrigel® were spread on top of the scaffolds as
single cells or in close proximity to mBMSCs (Fig. 4b) or
growing inside scaffold pores attached to the Matrigel® sur-
face (Fig. 4b; Additional file 6: Figure S5). After 14 days, the
cell density was significantly increased but cells were pre-
dominantly positioned on top of the scaffolds/Matrigel,
indicating that Matrigel does not support the migration
of HSPCs due to high density and overall low porosity
(Additional file 6: Figure S5). This hypothesis was sup-
ported by imaging using SEM in cryo-mode (Additional
file 6: Figure S5ii–iii). The Matrigel® porosity—as a re-
sult of the gelation process—was higher at the top part
of the gel and lower at the bottom, a limitation which
eventually led to the rare cell migration into the Matrigel®.
Collagen I/III gels showed high cell densities on top as
well as significant migration of hematopoietic cells inside
the gel and cells growing in close proximity to mBMSCs
and collagen fibers (Additional file 7: Figure S6). Similarly,
the addition of β-TCP to collagen I/III gels supported cell
proliferation as well as migration both in the murine and
human settings (Additional file 3: Figure S2B; Additional
file 8: Figure S7A, B). In β-TCP scaffolds, the cell prolifer-
ation and density appeared significantly impaired despite
the presence of a robust mBMSC layer covering the β-
TCP surfaces (Additional file 8: Figure S7A, B). This leads
to the suggestion that β-TCP scaffolds are supportive of
the growth of mBMSCs but that hematopoietic cells re-
quire an additional matrix structure.
Characterization of the β-TCP/matrix hybrids as extrame-
dullary hematopoietic niches in vivo
To test the capacity of β-TCP scaffolds for supporting
recruitment of hematopoietic cells and extramedullary
hematopoiesis, 500- and 800-μm β-TCP scaffolds pre-
seeded with mBMSCs were transplanted subcutaneously
into C57BL/6 mice in the presence and absence of colla-
gen I/III or Matrigel®. Hematopoiesis in the explanted
scaffolds was evaluated 4 and 8 weeks after transplant-
ation by flow cytometry, immunohistochemistry, and
SEM (Figs. 5 and 6).
We performed H&E staining (Fig. 5a, b) in order to
analyze the tissue and cell organization within the scaf-
folds. Histomorphological overviews in low magnification
demonstrated that all scaffold pores—both in the periph-
ery and in the central areas—were composed of a strongly
vascularized extracellular matrix, partially adipose tissue,
prominent histocyte-like cells aligning the β-TCP surface,
and accumulations of hematopoietic cells in close proxim-
ity to vessels and the β-TCP surface (Fig. 5a). Higher mag-
nification demonstrated dense clusters of hematopoietic
cells in particular at the scaffold/matrix interface (Fig. 5b).
CD31 immunohistochemistry confirmed a dense vas-
cular network in the scaffold, an important requisite for
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successful long-term engraft of scaffolds and recruitment
of hematopoietic cells (Fig. 5c). CD31-positive cells were
also seen at the β-TCP/tissue interface. CD45 staining
highlighted the spatial organization of hematopoietic
cells in dense clusters in proximity to both the vascula-
ture and the scaffold interfaces (Fig. 5c). As observed in
Fig. 4 Analysis of trilineage differentiation of c-kit+ HSPCs on β-TCP scaffolds in vitro. a Differentiation potential of c-kit+ cells cultured for 4 and
14 days on β-TCP scaffolds with and without collagen I/III gel/Matrigel® in the presence of MSC support: granulocytes (Gr1+CD11b+), monocytes
(Gr1−CD11b), erythroid precursor cells (Gr1−CD11b−CD3−CD19−), and T cells (Gr1−CD11b−CD3+). Percentage of viable cells is shown as mean ± SD
of three independent experiments. b SEM of c-kit+ cells cultured on 500-μm β-TCP/Matrigel® scaffolds. Very left column highlights cell spreading
and detailed cell morphology of day 4 and day 14 cultures. C-kit+-derived cells (red arrows) are in close contact to MSCs (white arrows). Cell extensions
at day 4 in detail (green arrow). View from the interior of the β-TCP macropores at day 14 (asterisk)
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Fig. 5 Histomorphology. 500μmor800μmβ-TCP scaffoldswerepre-seededwithmBMSC in thepresenceor absenceofMatrigel®. Scaffoldswere transplanted subcutane-
ously intoC57B1/6mice and analyzed for hematopoietic cell recruitment to sites of extramedullar hematopoiesis andhematopoietic tissue formationafter 4 and8weeks.a
Hematoxilin-eosin (HE) stainingof the explanted scaffolds 8weeks after transplantations.Magnification 100x.bHighermagnificationof theexplanted scaffolds after 8weeks.
Magnification 200x. c Immunohistochemistry for theendothelial surfacemarker CD31 and thepan-hematopoieticmarker CD45 in explanted scaffolds 8weeks after
transplantation.dHE stainingandby SEM for the identificationof osteoclasts at theborder of theβ-TCP scaffoldmacropores in explants 4weeks after transplantation
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Fig. 6 a SEM imaging of the explanted scaffolds 4 weeks after transplantation. White arrows: erythrocytes; black arrows: T cells; red arrows: thrombocytes;
gray arrow: neutrophils/granulocytes; asterisk: β-TCP. b-c Gating strategy for the flow cytometry: Hematopoietic stem (LSK) and progenitor cells (LK)
were identified by being negative for lineage markers and by the expression of Sca1 and c-kit. Lineages were identified by the following stainings:
granulocytes (Gr1+CD11b+), monocytes (Gr1−CD11b−), erythroid precursor cells (Gr1−CD11b−CD3−CD19−), T cells (Gr1−CD11b−CD3+), B cells (Gr1
−CD11b−CD19+). d Flow cytometry analysis of the explanted scaffolds 4 weeks after transplantations. Surface marker expression is shown as a percent-
age of the viable cell population; mean ± SD of three independent experiments
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vitro, the β-TCP surface seeded with mBMSCs appears
to provide appropriate conditions for the development
of a bone-like niche, as we also noted the presence of
multinucleated osteoclasts and osteoblasts. The presence
of osteoclasts was confirmed by SEM showing spindle-
shaped cells with brush-like microvilli (Fig. 5d).
We next sought to characterize the identity of
hematopoietic cells (Fig. 6a–d). All β-TCP/matrix hybrid
combinations were able to recruit hematopoietic cells to
the site of transplantation as SEM confirmed hematopoietic
cells inside the pores of the transplanted scaffolds (Fig. 6a).
Our first question was whether the implanted scaf-
folds promote extramedullary hematopoiesis including
the presence of hematopoietic stem and progenitor
cells. Flow cytometry confirmed the presence of cells of
all hematopoietic lineages: myeloid (CD11b+Gr1+),
lymphoid (Gr1−CD11b−CD19+ or CD3+), and erythroid
(Gr1−CD11b−CD19−CD3− Ter119+) lineages (Fig. 6c,
d). We did not detect an HSC-enriched LSK population
but hematopoietic progenitor cells as indicated by the
presence of lineage-negative and also myeloid progenitor
cells (LK population). These data indicate that the major-
ity of hematopoietic cells were recruited to the site of
transplantation and do not represent in situ, extramedul-
lary hematopoiesis. We did not observe significant differ-
ences in the recruitment of cell lineages in the different
culture conditions, demonstrating that all conditions are
suitable for ectopic transplantation independently of β-
TCP pore size or presence of extracellular matrix.
Discussion
The BM microenvironment is not transplantable making
it challenging to dissect the regulatory mechanisms
within the BM niche. We envisioned a widely available,
easy reproducible, simple, and well-defined system for
the creation of a transplantable human BM microenvir-
onment. Establishing such a system would include not
only a detailed characterization of the hematopoietic and
mesenchymal fractions upon culture/transplantation but
also the design of an appropriate scaffold material and
structure. For the co-culture of HSPCs and mBMSCs/
hMSCs, we applied β-TCP-printed scaffolds containing
macro- and micropores similar to the bone—of inor-
ganic (hydroxyapatite mineral) composition—in combin-
ation with an extracellular matrix gel—of organic
(collagen type I matrix) composition.
As β-TCP materials are unstable when exposed to
body fluids due to their small granule size, porosity, and
higher dissolution rate compared to other types of bio-
ceramics [27], we first set up to analyze the effects of β-
TCP dissolution on the cultured cells. Typically high
phosphate levels induce osteogenic differentiation, so we
asked whether or not β-TCP scaffolds in our setting in-
duced spontaneous osteogenic differentiation of MSCs
by Ca/P release to the culture media. Our analysis re-
vealed negligible Ca/P release and the exclusion of the
possibility for spontaneous MSC-derived osteogenesis
that could be detrimental for hematopoietic production.
Importantly, we showed that our β-TCP scaffolds have
the ability to support MSC growth and extracellular
matrix production in cultures up to 8 weeks without
limiting effects.
Our in vitro data suggest that complete hematopoiesis
is promoted by β-TCP scaffolds in combination with
structural proteins and cytokines provided by Matrigel®.
First, β-TCP/Matrigel® scaffolds more robustly main-
tained a primitive LSK fraction over time, with the
Matrigel® component being responsible for maintenance
of HSPCs within the scaffolds. Second, hematopoietic
differentiation in both myeloid and lymphoid lineages
was supported after 14 days in Matrigel®-containing con-
ditions. Third, the CFU potential of β-TCP/Matrigel®
scaffolds was significantly increased compared to other
conditions implicating that Matrigel supports both the
functional maintenance of HSPCs and their differenti-
ation capacity. Fourth, β-TCP/Matrigel® scaffolds sup-
ported the remodeling of the ECM as an important
requisite for cell differentiation and growth.
In vivo, β-TCP/Matrigel® scaffolds resulted in strong
hematopoietic recruitment to the sites of the ectopic
transplantations as confirmed by the detection of myeloid
and lymphoid fractions 4 weeks after transplantations at
levels comparable to the relative composition of the BM.
Multinucleated osteoclasts and typically spindle-shaped
osteoblasts were seen at the β-TCP scaffold/ECM inter-
face. CD31-positive layers of recruited endothelial cells
and adipose cells, typical for vascular niches, were both
identified in explants showing the most efficient collagen
matrix deposition. Adipose cells were regarded as simple
as BM fillers but are now known to be negative regulators
of the hematopoietic microenvironment [28]. BM tissue
formation in our setting was mainly promoted by Matri-
gel®, a biodegradable basement membrane protein ex-
tracted from Engelbreth-Holm-Swarm sarcoma mouse
cells, typically used to recreate 3D environments stimulat-
ing tissue formation. The main components of Matrigel®
are known to be structural proteins laminin, collagen IV,
and enactin, but numerous other intracellular proteins are
present. Around 1300 proteins (either cytoplasmatic or
nuclear) were identified in Matrigel® composition, and
among those were collagen IV; actin; spectrin; tubulin;
dynactin; filamin structural proteins like fibronectin, dy-
nein, desmin, myosin, transferrin; and intracellular pro-
teins such as adenylate kinase and heat shock family
members [29]. Additionally, specific growth and transcrip-
tion factors such as kruppel-like factor 6, kruppel-like fac-
tor 15, and connective tissue growth factor were
identified. Future studies will be necessary to dissect
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which of these factors are most important to support both
hematopoiesis and osteogenesis to generate more defined
environments.
Our study demonstrates that varying pore sizes of the
β-TCP scaffolds from 500 to 800 μm was irrelevant in
terms of hematopoietic support function. This is an in-
teresting finding as particle geometry, porosity, pore size
distribution, and scaffold continuity are properties
known to determine cell/scaffold interactions and thus
cell fate [20, 30, 31]. Pore size, however, has been only
considered crucial within three main pore size intervals.
According to Petite et al., pore sizes smaller than 15–
50 μm result in fibrovascular growth, medium-sized
pores of 50–150 μm encourage osteogenesis, while pores
larger than 150 μm support the ingrowth of mineralized
bone [20]. Contradicting studies even report that bone
ingrowth is optimal for pore sizes varying from 300 to
900 μm [22].
The β-TCP scaffolds applied in our study had an inter-
connected net-like structure in the absence of dead-end
pockets, macropores with mean pore size 500 or
800 μm, and micropores smaller than 15 μm. Our scaf-
folds were designed to maximize the surface area for
stromal cell expansion, and we were able to demonstrate
that these characteristics successfully promote vascular
ingrowth as well as promotion of hematopoiesis.
Our engineered bone marrow has the potential to be
applied for drug discovery studies and leukemia therapy
as well as stem cell transplantation research [32, 33].
Conclusions
We introduce a multicomponent system that is optimal
for the study of hematopoietic-mesenchymal interactions
and the recapitulation of the native BM microenvironment
in a transplantable mouse model. Macro- and micropor-
ous β-TCP scaffolds in combination with a Matrigel®-based
component optimally supported hematopoiesis, including
hematopoietic recruitment, proliferation, and differenti-
ation as well as ECM remodeling. β-TCP/Matrigel® scaf-
folds further promoted vascularization and allowed for
mature bone deposition and hematopoiesis—stroma inter-
actions in subcutaneous ectopic transplantations of the
BM niche in a murine model.
Additional files
Additional file 1: Table S1. Primers used for RT-qPCR.
Additional file 2: Figure S1. Representative SEM images of 500- or
800-μm β-TCP scaffolds pre-seeded with hMSCs maintained in culture for
3 weeks with or without addition of collagen I/III. Collagen I/III embedded with
hMSCs cultured under standard conditions were undifferentiated
controls. Collagen I/III gels with embedded hMSCs cultured under
osteogenic differentiation conditions were osteogenic controls (xii).
Additional file 3: Figure S2. (A) Monitorization of the CD34+CD38−
primitive phenotype in human-derived CD34+ progenitors co-cultured
with hMSCs for 5 and 12 days in the different β-TCP/matrix hybrids. On
the left data presented is a mean ± SD of three independent experiments;
on the right, dot plots of one representative experiment are shown. (B)
Representative SEM images CD34+ HSPCs co-cultured for 12 days in 800-
μm β-TCP scaffolds in the presence of hMSC-containing collagen I/III
matrix. CD34+ HSPCs (red arrows) are seen in close contact to hMSCs
(white arrows) within the scaffold macropores. β-TCP scaffolds (asterisks)
were reinforced with collagen I/III (green arrows).
Additional file 4: Figure S3. Dot plot representations of the putative
LSK (lin−Sca1+c-kit+) population in starting cultures and 4-, 7-, and 14-day
cultures of c-kit+-isolated cells in co-culture with mBMSCs on 500- and
800-μm β-TCP scaffolds with or without collagen I/III gels or Matrigel®.
Flow cytometry data shown is of one representative experiment.
Additional file 5: Figure S4. (A) Representative TEM images of c-kit+
cells used for initiating co-cultures after immunomagnetic bead selection.
(B) TEM images of 4- and 14-day cultured c-kit+ cells on 500-μm β-
TCP scaffolds, 500-μm β-TCP/collagen I/III scaffolds, and 500-μm β-
TCP/Matrigel® scaffolds. Collagen I/III gels and Matrigel® alone are
shown as controls. C-kit+ progenitor cell morphology (of freshly isolated
cells) consisting of visible scattered chromatin, prominent nucleoli,
and approximated cell diameter of 8–10 μm is shown as reference.
Additional file 6: Figure S5. Representative SEM images of Matrigel®
scaffolds pre-seeded with mBMSCs and later seeded with c-kit+-isolated
cells; co-cultures were maintained for 14 days (i, iv, v, vii). Detailed morphology
of c-kit+-derived cells that had migrated inside the Matrigel® after 4 days in
culture are also shown (vi, viii, ix). SEM in cryogenic mode (ii) and dry mode
(iii) was done to analyze in detail the raw (empty) structure of Matrigel®.
Additional file 7: Figure S6. Representative SEM images of collagen I/
III gels pre-seeded with mBMSCs and later seeded with c-kit+-isolated
cells. Co-cultures observed were maintained for 4 days (vi) and 14 days (i,
iv, v). SEM in cryogenic mode (ii) and dry mode (iii) shows the typically
high microporosity rate of collagen I/III.
Additional file 8: Figure S7. (A) Representative SEM images of 800-μm β-
TCP scaffolds pre-seeded with mBMSCs and seeded with c-kit+-isolated cells.
Images of 4-day cultures (i-iii) and 14-day cultures (iv-vi) are shown.
(B) All conditions similar to (A) except 800-μm β-TCP/collagen I/III
scaffolds were used.
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